Clinicians have seen remarkable progress in cancer patients treated with the class of immunotherapy drugs known as checkpoint inhibitors. In a small number of patients, they have also seen a rare but fatal cardiovascular side effect known as myocarditis.

Now, with checkpoint inhibitors likely to be approved for a wider array of cancers, researchers are concerned that it’s only a matter of time before more patients develop the same autoimmune response. They still don’t know why.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am hoping that those who are going through the immunotherapy treatment protocol, are discussing this issue with their doctors, especially if they are experiencing symptoms of what has been described as myocarditis.

    It is important that patients have access to the information, that is conveyed in this article. Thank you for addressing this topic.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy